Print This Page

Important Safety Information Full Prescribing Information


Dosing and Administration

ALOXI® dosing and administration

  • A single 0.25 mg IV dose administered over 30 seconds
  • Dosing should occur approximately 30 minutes before the start of chemotherapy

Aloxi for injection

  • A clear, colorless, isotonic, buffered solution for intravenous administration
  • Available as 5 mL single use vial

Storage requirements

  • Store at controlled temperature of 68ºF-77ºF (20ºC-25ºC); excursions permitted to 59ºF-86ºF (15ºC-30ºC)
  • Protect from freezing
  • Protect from light

Indication

In adults, ALOXI® (palonosetron HCl) injection 0.25 mg is indicated for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy, and acute nausea and vomiting associated with initial and repeat courses of highly emetogenic chemotherapy.

Important Safety Information

  • Aloxi is contraindicated in patients known to have hypersensitivity to the drug of any of its components
  • Most commonly reported adverse reactions in chemotherapy-induced nausea and vomiting include headache (9%) and constipation (5%)

For more information about ALOXI, please see Full Prescribing Information

Sitemap | Legal Notice and Disclaimers | Privacy

This information is intended for use by healthcare professionals in the United States only. Eisai Inc. recognizes that the Internet is a global communications medium; however, laws, regulatory requirements and medical practices for pharmaceutical products vary from country to country. The Prescribing Information included here is not appropriate for use outside the United States.

ALOXI® is a registered trademark of Helsinn Healthcare SA, Switzerland, used under license.
Distributed and marketed by Eisai Inc.
© 2010 Eisai Inc.
All rights reserved. AL562B 7/10